Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
September 17 2024 - 11:45AM
UK Regulatory
Idorsia continues to further the science of sleep and insomnia with
new daridorexant data and analyses published at Sleep Europe 2024
Allschwil, Switzerland – September 17,
2024
Idorsia Ltd (SIX: IDIA) today announced that new data and
analyses of daridorexant, Idorsia’s dual orexin receptor antagonist
for the treatment of adults with chronic insomnia, will be
presented at Sleep Europe 2024 – the 27th Congress of the European
Sleep Research Society (ESRS), taking place in Seville, Spain,
September 24–27, 2024.
The following posters will be presented:
- Lederer K, et al. Efficacy and safety
of daridorexant in patients with chronic insomnia disorder and
comorbid nocturia [P5021], Wednesday, Sep 25, 12:15 – 13:15 and
16:00 – 17:45.
- McCall WV, et al. Dose-response of
daridorexant in insomnia disorder: a meta-analysis of Phase 2 and 3
studies [P298], Wednesday, Sep 25, 12:15 – 13:15 and 16:00 –
17:45.
- Dauvilliers Y, et al. Effect of
daridorexant on wakefulness throughout the night and morning
sleepiness in patients with insomnia disorder [P1213], Friday, Sep
27, 10:45 – 13:30.
- Boof M-L, et al. Repeated dosing of 50
mg daridorexant in patients with severe obstructive sleep apnea:
Effect on sleep-disordered breathing and sleep [P1200], Friday, Sep
27, 10:45 – 13:30.
- Muehlan C, et al. Nighttime Safety of
Daridorexant: Response to Noise Stimuli, and effects
on Postural Stability, Walking and Memory [P1197],
Friday, Sep 27, 10:45 – 13:30.
- Kaufmann P, et al. Excretion of the
Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of
Healthy Lactating Women [P1196], Friday, Sep 27, 10:45 –
13:30.
- Di Marco T, et al. Effect of
daridorexant on sleep micro-architecture in adult patients with
insomnia disorder – A post-hoc analysis of two pooled Phase 3
studies [P1198], Friday, Sep 27, 10:45 – 13:30.
- Lettieri CJ, et al. Effect of
Daridorexant on Patients with Comorbid Insomnia Disorder and
Untreated Mild Obstructive Sleep Apnea: A Post-hoc Analysis of a
Phase 3 Study [P1201], Friday, Sep 27, 10:45 – 13:30.
The abstracts can be found on the congress
website.
In addition, Idorsia is supporting a satellite symposium
entitled "Overactive wake-signaling and the management of insomnia
disorder" on Thursday, September 26, from 12:15-13:15 CEST in Room
“Paris 2”. The symposium will be hosted by Diego Garcia-Borreguero
(Spain), Yves Dauvilliers (France), Laura Palagini (Italy), and
Christina Lang (Germany), and will explore the latest standard of
care for patients with chronic insomnia.
Notes to the editor
About daridorexant
Daridorexant is a dual orexin receptor antagonist (DORA) which
blocks the binding of the wake-promoting orexin neuropeptides.
Rather than inducing sleep through broad inhibition of brain
activity, daridorexant selectively blocks the activation of orexin
receptors. Consequently, daridorexant reduces overactive wake
signaling, allowing sleep to occur and working throughout the night
without altering the proportion of sleep stages. Daridorexant is
commercially available as QUVIVIQ in the US, Germany, Italy,
Switzerland, Spain, the UK, Canada, Austria, and France, and is
approved throughout the EU and in Hong Kong.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 25-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 750 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Idorsia (LSE:0RQE)
Historical Stock Chart
From Dec 2023 to Dec 2024
